med-tech recap preview
conf point continu solid growth
earn preview op bmo expect solid momentum
continu posit deliv result expect
roughli in-lin management guidanc organ sale growth despit stronger-
than-expect result expect stock react favor result
organ growth estim estim ep reiter outperform
alc earn op expect meet beat sale
ep estim cse bil sale cc ep topic conf
call panoptix uptak launch contact len trend op mgn leverag
fx estim tougher expect reiter outperform
pcr london valv london focu transcathet heart valv
includ aortic mitral
outperformed-r ew
veith symposium vascular endovascular new york focu
veith symposium intervent cardiolog vascular endovascular
diseas expect implic outperformed-r
cs healthcar confer take-away host number compani
annual credit suiss healthcar confer scottsdal az came away
increment posit fundament growth driver
robust sale growth vs cse rais target price management
deliv third consecut beat driven primarili upsid purapli narrow
guidanc reiter outperform target price rais post result
first intra-quart look scrip point solid start analysi octob
scrip trend point growth major drug includ analysi roughli
line expect reiter outperform
ms index ytd bp bp ms
ltm vs ms led group week
ew lead ytd lc growth diversifi ms
ntm ev/ebitda respect vs
figur weekli perform suppli devic ms
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
figur upcom event catalyst
ticker potenti implic
cover
updat model downgrad neutral deal
downgrad neutral follow syk announc pend deal
rais price target in-lin term deal
holt weekli analysi attract holt market impli
expect reveal attract holt market impli
expect indic valuat conserv healthcar subsector
med-tech appear fairli price
figur week read research medic suppli devic
agreement principl opioid reduc uncertainti sop analysi support upsid rais target price reiter outperform
impress growth ep upsid underscor strength fundament cadenc new product drive continu growth
acceler path categori leadership top shoulder robot strategi posit also lower extrem reiter outperform
explor potenti sale report initi take question
third-parti lab find asbesto re-test babi powder sampl fda stand contractor result
solid ep upsid pharma preview boost better expect devic consum
organ growth track challeng fx top end ep reiter outperform
us robot acceler ortho implant drive sale ep despit tougher fx rais target price reiter outperform
first intra-quart look scrip solid start reiter outperform target price
confer call event detail
midnight et us passcod
med-tech recap preview
outperform-r report result novemb view underli growth
outlook solid in-lin believ new product launch pipelin
posit compani sustain growth estim organ
ep roughli line management guidanc believ compani well-posit
exceed expect topic call pipelin updat updat approv
launch timelin robot tavr updat diabet updat includ us/ou
med-tech recap preview
guidancecon cs estimate guidancecon cs estimate con cs growth growth growth growth growth cc growth end growth cc growth growth cc growth growth cc growth minim trend emerg technolog insulinpump salesupd robot sale spine share well db focu advanc surgic advanc us tavr growth paclitaxel/dcb trend updat micra av expect tyrx post wrap-it trial resultsexpect in-lin better ep charl martineau pm univers toronto novemb
outperform-r alc report result novemb model sale bil
cc growth ep estim quarter in-lin
consensu top-lin bottom-lin driven fx estim
recal core oper margin last quarter neg impact bp
fx continu see fx pressur compani topic call updat
panoptix launch follow earlier expect approv ou panoptix perform
contact len sale daili growth capit equip equip
servic perform systan complet perform updat ou launch
attend upcom american academi ophthalmolog meet
expect get first look panoptix trifoc iol well initi clinician feedback
med-tech recap preview
con cs estimate con cs estimate con cs in-lin better ep revenuesy/i growth growth growth growth growth growth growth daili dispos updat panoptix launch at-iol charl martineau pm univers toronto novemb
announc robert ford succeed mile white ceo
novemb announc chairman ceo mile white
step march robert ford current presid
succeed mr white abt ceo mr white continu execut
chairman board
new analysi credenc studi show efficaci safeti
profil invokana consist across variou level kidney
function novemb announc result new analysi
phase credenc studi american societi nephrolog
kidney week found invokana canagliflozin
consist reduc risk renal cardiovascular event patient
variou level kidney function estim glomerular filtrat rate
egfr secondari analysi invokana lower risk cv
renal event patient across egfr subgroup invokana also led
fewer advers event seriou advers event overal consist
canagliflozin renal event diabet establish nephropathi
clinic evalu random double-blind event-driven placebo-
control parallel-group multicent studi evalu
patient stage dkd defin egfr
macroalbuminuria defin urinari albumin-to-
creatinin ratio acr mg/g receiv standard
care includ maximum toler label daili dose angiotensin-
convert enzym ace inhibitor angiotensin ii receptor blocker arb
primari efficaci outcom analys composit
eskd dialysi transplant egfr doubl serum creatinin
renal death cv death specifi secondari outcom includ
composit heart attack stroke cv death composit cv death
hospit heart failur
tremfya meet primari endpoint superior respons vs
placebo week phase psoriat arthriti studi
significantli greater proport patient activ psoriat arthriti
treat tremfya guselkumab achiev least improv
diseas sign symptom american colleg rheumatolog
respons compar placebo find repres primari
endpoint phase studi
design evalu efficaci safeti investig use
tremfya treatment adult patient activ result
show week adult patient activ
receiv tremfya everi four week patient receiv tremfya
week everi eight week thereaft achiev
respons compar patient receiv placebo among patient
percent bodi surfac area bsa affect psoriasi
investig global assess iga score baselin
patient receiv tremfya patient receiv tremfya
achiev iga score clear minim grade reduct
compar percent patient receiv placebo
context random double-blind multicent phase
studi evalu efficaci safeti tremfya administ
subcutan inject particip activ psoriat arthriti includ
med-tech recap preview
previous treat biolog anti-tnf alpha agent
studi consist screen phase six week blind treatment
phase week includ placebo-control period week
week activ treatment period week week
safeti follow-up phase eight week week result
show week adult biologic-na patient
activ receiv tremfya respect achiev
respons compar patient receiv placebo among
patient percent bsa affect psoriasi iga
score baselin receiv tremfya receiv
tremfya achiev iga score grade reduct
baselin compar patient receiv placebo discover-
random double-blind multicent phase studi evalu
efficaci safeti tremfya administ subcutan inject
subject activ psoriat arthriti studi consist
screen phase
approxim week includ placebo-control period
week week activ treatment period week week
safeti follow-up phase week last administr
studi agent
six week blind
announc submiss snda fda seek approv
imbruvica combin rituximab novemb
announc submiss supplement new drug applic snda
fda seek approv expand imbruvica ibrutinib label
includ combin rituximab first-lin treatment patient
chronic lymphocyt leukemia cll small lymphocyt lymphoma
sll submiss base result investig phase
studi studi met primari endpoint progression-fre
surviv overal surviv os patient age year younger
treat imbruvica plu rituximab compar chemoimmunotherapi
regimen fludarabin cyclophosphamid rituximab fcr context
head-to-head clinic trial imbruvica-bas regimen vs fcr
common chemoimmunotherapi regimen establish
date frontlin treatment younger adult patient cll
withdraw regulatori file extend indic opsumit
cteph novemb announc actelion decid
voluntarili withdraw european health author file still
review extend indic opsumit macitentan includ
treatment adult inoper chronic thromboembol pulmonari
hypertens cteph withdraw submiss base phase
result macitentan treatment inoper chronic
thromboembol pulmonari hypertens studi driven
safeti concern compani intend gener addit data
support futur cteph file receiv feedback health author
 eu addit clinic data would requir
result marvel significantli improv synchroni
cardiac function novemb announc result
show investig set algorithm micra transcathet
pace tp significantli improv synchroni cardiac function
patient impair electr conduct chamber
heart call atrioventricular av block base result
marvel marvel studi submit new leadless
med-tech recap preview
pacemak micra av expand indic popul av block
normal sinu rhythm current fda review context
marvel studi evalu patient micra tp evalu
safeti effect accelerometer-bas atrial sens algorithm
download micra tp devic studi primari
efficaci object met significantli greater percentag
complet heart block patient normal sinu rhythm av
synchroni algorithm-medi av synchron pace
patient pace patient proport
patient synchroni addit studi primari safeti
object met paus episod pacing-induc tachycardia
report algorithm mediat av synchron pace
med-tech recap preview
figur last week med-tech bp bp bp hc
med-tech recap preview
figur last month disrupt ms lead ms
disrupt ms index pro-rata weight perform alc ew base
proport revenu driven disrupt technolog
med-tech recap preview
figur last month disrupt ms index outperform smid lc
disrupt ms index pro-rata weight perform alc ew base
proport revenu driven disrupt technolog
med-tech recap preview
figur ntm ev/ebitda coverag univers
med-tech recap preview
med-tech recap preview
holt market impli expect analysi indic valuat conserv
healthcar subsector holt use revers dcf quantifi market impli
expect calcul futur level return capit cfroi requir justifi
today valuat market impli expect green dot consensu
forecast pink bar indic attract valuat upsid potenti stock
figur healthcar holt cfroi ntm forecast return capit vs market-impli spread
note aggreg ex financi regul util reit data shown base constitu median
med-tech recap preview
return capit cfroi histor forecast market impli median industryspread forecast vs market impli return capitalconserv expect current price impli declin returnsdemand expect current price impli increas plife scitot hcmedtechposit spread currentneg spread year median plife scitot hcmedtechcfroi year mediancfroi lfycfroi consensu forecast ntm market impli charl martineau pm univers toronto novemb
market impli expect coverag univers med-tech gener demand
rel sell side forecast holt market impli expect analysi reveal
attract consensu forecast cfroi market impli
expect demand expect
figur med-tech holt cfroi ntm forecast return capit vs market-impli spread
contact inform holt
med-tech recap preview
return capit cfroi histor forecast market impliedspread forecast vs market impli return capit conserv expect current price impli declin returnsdemand expect current price impli increas spread currentneg spread year median mediancfroi lfycfroi consensu forecast ntm market impli charl martineau pm univers toronto novemb
compani mention price
